Cloud based drug safety data aggregation platform provides powerful insights using both Advera Health curated data and structured internal and alternative safety data sources. Powered by the proprietary RxFilter® data optimization technology, Evidex supports a broad array of safety signal detection and risk mitigation use cases.
Clean, standardized data architecture and RxFilter® data optimization technology allow for simple and efficient intake of third party data sources into Evidex. Straight forward APIs help power leading enterprise software applications to feed Advera Health data into their applications.
Comparative research that provides evidence reviews of new and soon-to-be launched drugs, insight into labeling changes and FDA safety communications, and evidence driven insight into other key drug issues.
Custom advisory services to aid market access and commercialization strategies using annotated data from curated clinical trials results and structured real world data. Support new drug launches, defend market position and help pharmaceutical companies tell their evidence based story.
Annotated data from curated clinical trial results. The most comprehensive safety focused trials database featuring data from ClinicalTrials.gov, published research, abstracts, presentations, and more.
Fully optimized FDA Adverse Event Reporting System (FAERS) data. Over 8 million case reports cleaned, standardized, de-duplicated, and dynamically linked using our RxFilter® data optimization technology.
Proprietary analytic tools that draw out actionable intelligence from the huge volumes of data we manage. All of our analytics are peer reviewed and published in major industry journals.
We work with pharmaceutical companies in a number of different business units to help them better understand, mitigate, navigate, and commercialize based on comparative safety issues in both clinical and approved drugs. Professionals across Drug Safety, Pharmacovigilance, HEOR, and Market Access rely on Advera’s data, analytics and insight to better monitor their own products as well as those of the competition.Learn more
We work with health insurers at the pharmacy and therapeutics (P&T) committee level to provide needed access to better clinical evidence and independent real world safety data that drive insights for efficient drug reviews and to ensure better prescribing decisions. Progressive insurers also use our data, analytics, and insight to quantify downstream medical costs, perform comparative safety reviews, and conduct drug utilization recommendationsLearn more
We work with hospitals and health systems in a number of departments to provide easier access to clinical evidence and independent real world safety data that drive insights for efficient drug reviews and to ensure better prescribing decisions. Healthcare decision makers from across Drug Information and Clinical Pharmacy rely on Advera’s data, analytics and insight to quickly make evidence based drug utilization decisions and benchmark in-facility adverse events against global datasets.Learn more
We work with product liability underwriters to access independent, real world safety data, analytics and insight in the underwriting process so that they can better assess potential litigation risk and fully understand the impact that risk could have on their insureds. Our simple to use and understand statistical risk assessment analytics enable an enterprise-wide solution that provide our clients with a complete understanding of the risk exposure in their life science business.Learn more
We work with U.S. and international academic institutions to study drug safety issues in both pipeline and approved drugs. With far reaching academic goals, clients come to us with needs ranging from outcomes research studies, pharmacology studies, and pharmacoepidemiology studies. In addition to providing access to our data and analytics, our expert analyst staff is equipped to support and advise on peer review poster and publication submissions.Learn more
We work with financial institutions looking for an information advantage about emerging drug safety issues. In a marketplace where information is key and safety concerns can quickly create stock price volatility, our data and analytics give our financial clients a needed early warning system.Learn more